Clinical Trial

Paediatric Hepatic International Tumour Trial

Study acronym: PHITT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2017-01-10; most recent amendment 2026-05-12.
Status change: Recruiting → Active, Not Recruiting 2024-05-09
Status change: Not Yet Recruiting → Recruiting 2017-10-25
Trial Details
NCT Number NCT03017326
Lead Sponsor University of Birmingham
Collaborators: Fundació Institut Germans Trias i Pujol, University Hospital Munich, University Hospital, Bonn, University of Kiel, University Hospital Tuebingen, University of Padova, Ludwig-Maximilians - University of Munich, Medical University of Gdansk, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Motol University Hospital, Rennes University Hospital, Children's University Hospital, Ireland, University of Oslo, Princess Maxima Center for Pediatric Oncology, Andaluz Health Service, Swiss Pediatric Oncology Group, Gothia Forum - Center for Clinical Trial, The Leeds Teaching Hospitals NHS Trust, Bambino Gesù Hospital and Research Institute, Newcastle University, Experimental Cancer Medicine Centres, XenTech, Evry
Conditions Hepatoblastoma, Carcinoma, Hepatocellular
Enrollment 450 participants
Start Date 2017-08-24
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-13